SCHEMBL9957903

SCHEMBL9957903

Cc1cccc(C)c1-c1cc(-c2c(C)cccc2C)nc(-c2cc[c]cc2)n1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.37
KMT2A Q03164 5/20 0.37
ALDH1A1 P00352 4/20 0.37
HPGD P15428 4/20 0.37
MAPT P10636 4/20 0.37
RAB9A P51151 1/20 0.36
LMNA P02545 4/20 0.36
KDM4E B2RXH2 2/20 0.36
GLA P06280 1/20 0.36
SRC P12931 2/20 0.35
DHFR P00374 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.34
ADORA2A P29274 1/20 0.34
ADORA1 P30542 1/20 0.34
CYP1A2 P05177 2/20 0.33
NTSR1 P30989 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
HTR7 P34969 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9958159 0.77 RAB9A (0.50) MEN1KMT2AALDH1A1HPGDMAPT
SCHEMBL2750595 0.76 CYP1A2 (0.38) ALDH1A1SRCCYP1A2HTR7
SCHEMBL9957739 0.74 NISCH (0.40) MEN1KMT2AALDH1A1HPGDMAPT
SCHEMBL9958264 0.73 MEN1 (0.60) MEN1KMT2AALDH1A1HPGDMAPT
SCHEMBL9958727 0.72 LMNA (0.47) MEN1KMT2AALDH1A1HPGDMAPT
SCHEMBL9958067 0.71 MEN1 (0.50) MEN1KMT2AALDH1A1HPGDMAPT
SCHEMBL28251645 0.71 ALDH1A1 (0.37) ALDH1A1SRCCYP1A2HTR7
SCHEMBL20251427 0.70 L3MBTL1 (0.50) MEN1KMT2AALDH1A1HPGDMAPT
SCHEMBL13312931 0.70 L3MBTL1 (0.48) MEN1KMT2AALDH1A1HPGDMAPT
SCHEMBL2753948 0.69 HTR7 (0.36) ALDH1A1CYP1A2HTR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9624193-B2 Cyclic azine derivatives, processes for producing these, and organic electroluminescent element containing these as component TOSOH CORPORATION (JP) 2017-04-18 US disclosed
US-20150329544-A1 CYCLIC AZINE DERIVATIVES, PROCESSES FOR PRODUCING THESE, AND ORGANIC ELECTROLUMINESCENT ELEMENT CONTAINING THESE AS COMPONENT TOSOH CORPORATION (JP) 2015-11-19 US disclosed
US-9120773-B2 Cyclic azine derivatives, processes for producing these, and organic electroluminescent element containing these as component TOSOH CORPORATION (JP) 2015-09-01 US disclosed
EP-2818462-A1 Cyclic azine derivatives, processes for producing these, and organic electrolumiscent element containing these as component TOSOH CORPORATION (JP) 2014-12-31 EP disclosed
US-20120214993-A1 CYCLIC AZINE DERIVATIVES, PROCESSES FOR PRODUCING THESE, AND ORGANIC ELECTROLUMINESCENT ELEMENT CONTAINING THESE AS COMPONENT SAGAMI CHEMICAL RESEARCH INSTITUTE, (JP) 2012-08-23 US disclosed
EP-2468731-A1 CYCLIC AZINE DERIVATIVES, PROCESSES FOR PRODUCING THESE, AND ORGANIC ELECTROLUMINESCENT ELEMENT CONTAINING THESE AS COMPONENT Tosoh Corporation (JP) 2012-06-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150329544-A1 CYCLIC AZINE DERIVATIVES, PROCESSES FOR PRODUCING THESE, AND ORGANIC ELECTROLUMINESCENT ELEMENT CONTAINING THESE AS COMPONENT CPNE4, EPB41, AZI2 MEN1 405/4885KMT2A 3592/4885ALDH1A1 267/4885
US-20120214993-A1 CYCLIC AZINE DERIVATIVES, PROCESSES FOR PRODUCING THESE, AND ORGANIC ELECTROLUMINESCENT ELEMENT CONTAINING THESE AS COMPONENT CPNE4, EPB41, AZI2 MEN1 405/4885KMT2A 3592/4885ALDH1A1 267/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.